Search

Displaying results 1241 - 1250 of 2674 in total
  1. Drug

    Nomifensine

    go.drugbank.com/drugs/DB04821
    ApprovedWithdrawn

    FDA published a notice of its determination that Merital capsules were removed from the market for safety reasons (see the Federal Register of June 17, 1986 (51 FR 21981)). … Approval of the NDA for Merital capsules was withdrawn on March 20, 1992 (see the Federal Register of March 20, 1992 (57 FR 9729)). Also withdrawn from the Canadian and UK markets.

  2. Drug

    Guselkumab

    go.drugbank.com/drugs/DB11834
    ApprovedInvestigational

    Guselkumab is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody that selectively blocks interleukin-23. IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade...

  3. Target

    G protein-coupled receptor family C group 5 member D

    go.drugbank.com/bio_entities/BE0010290
    TargetHumans

    G protein-coupled receptor involved in hard keratin expression and likely plays a role in the development of hair and nails

    Polypeptides: G protein-coupled receptor family C group 5 member DFunction: G protein-coupled receptor activity
  4. Drug

    Crizotinib

    go.drugbank.com/drugs/DB08865
    ApprovedInvestigational

    [A250785] Crizotinib was approved by the FDA in 2011, and its use is accompanied by FDA-approved tests used to detect ALK and ROS1 rearrangements.[L42460] … Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic

    Categories: Receptor Tyrosine Kinase Inhibitors
  5. Drug

    Normethadone

    go.drugbank.com/drugs/DB11609
    ApprovedIllicit

    Normethadone is used as an opioid antitussive in combination with DB11610. It is marketed in Canada by Valeant under the tradename Cophylac.

  6. Drug

    Rilpivirine

    go.drugbank.com/drugs/DB08864
    ApprovedInvestigational

    [A31331] Rilpivirine was developed by Tilbotec, Inc. and FDA approved on May 20, 2011. … [L1031] Rilpivirine in combination with [cabotegravir] was granted FDA approval on 21 January 2021.

  7. Drug

    Adagrasib

    go.drugbank.com/drugs/DB15568
    ApprovedInvestigational

    [L44361,L44366] Adagrasib joins [sotorasib] as another KRAS<sup>G12C</sup> inhibitor approved by the FDA.[A254062] … [A254052,A254057,A254946] In February 2022, the FDA accepted a new drug application (NDA) for adagrasib for the treatment of patients with previously treated KRAS<sup>G12C</sup>–positive NSCLC.

  8. Drug

    Ipratropium

    go.drugbank.com/drugs/DB00332
    ApprovedInvestigational

    [A176957] Ipratropium as a therapeutic agent was developed by Boehringer Ingelheim and its first monotherapy product was FDA approved in 1986, while the combination product of ipratropium and [albuterol

  9. Drug

    Melphalan flufenamide

    go.drugbank.com/drugs/DB16627
    ApprovedWithdrawn

    [A230143,L32173] Melphalan flufenamide was granted FDA approval on 26 February 2021.[L32173].

  10. Target

    6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4

    go.drugbank.com/bio_entities/BE0003931
    TargetHumans

    Synthesis and degradation of fructose 2,6-bisphosphate

    Synonyms: 6PF-2-K/Fru-2,6-P2ase 4, 6PF-2-K/Fru-2,6-P2ase testis-type isozyme